Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

Philippe Ruszniewski,Sofia Ish-Shalom,Machteld Wymenga,Dermot O'Toole,R. Arnold,Paola Tomassetti,Nigel Bax,Martyn Caplin,Barbro Eriksson,Benjamin Glaser,Michel Ducreux,Catherine Lombard-Bohas,Wouter W. de Herder,Gianfranco Delle Fave,Nick Reed,Jean-François Seitz,Eric Van Cutsem,Ashley B. Grossman,Philippe Rougier,Wolfgang Schmidt,Bertram Wiedenmann

Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide

2004

This 6-month, open, non-controlled, multicenter, dose-titration study evaluated the efficacy and safety of 28-day prolonged-release (PR) lanreotide in the treatment of carcinoid syndrome. Eligible pat

Keywords:

Lanreotide
Octreotide acetate
5-Hydroxyindoleacetic acid
Malignant Carcinoid Syndrome
VIPoma
Somatostatin
Endocrinology
Internal medicine
Carcinoid syndrome
Medicine
prolonged release

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

131

Citations